DK3554490T3 - Farmaceutisk kombination omfattende en calciumkanalblokker type T - Google Patents

Farmaceutisk kombination omfattende en calciumkanalblokker type T Download PDF

Info

Publication number
DK3554490T3
DK3554490T3 DK17828874.2T DK17828874T DK3554490T3 DK 3554490 T3 DK3554490 T3 DK 3554490T3 DK 17828874 T DK17828874 T DK 17828874T DK 3554490 T3 DK3554490 T3 DK 3554490T3
Authority
DK
Denmark
Prior art keywords
calcium channel
channel blocker
pharmaceutical combination
blocker type
type
Prior art date
Application number
DK17828874.2T
Other languages
English (en)
Inventor
Melanie Kessler
Catherine Roch
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Application granted granted Critical
Publication of DK3554490T3 publication Critical patent/DK3554490T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK17828874.2T 2016-12-16 2017-12-15 Farmaceutisk kombination omfattende en calciumkanalblokker type T DK3554490T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2016081455 2016-12-16
PCT/EP2017/082981 WO2018109152A1 (en) 2016-12-16 2017-12-15 Pharmaceutical combination comprising a t-type calcium channel blocker

Publications (1)

Publication Number Publication Date
DK3554490T3 true DK3554490T3 (da) 2022-02-28

Family

ID=60957267

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17828874.2T DK3554490T3 (da) 2016-12-16 2017-12-15 Farmaceutisk kombination omfattende en calciumkanalblokker type T

Country Status (27)

Country Link
US (1) US11213517B2 (da)
EP (1) EP3554490B1 (da)
JP (2) JP6931701B2 (da)
KR (2) KR102296653B1 (da)
CN (1) CN110072521B (da)
AU (2) AU2017378092B2 (da)
BR (1) BR112019011208A2 (da)
CA (1) CA3046846A1 (da)
CL (1) CL2019001628A1 (da)
DK (1) DK3554490T3 (da)
EA (1) EA201991428A1 (da)
ES (1) ES2908641T3 (da)
HR (1) HRP20220463T1 (da)
HU (1) HUE058360T2 (da)
IL (1) IL267306B (da)
LT (1) LT3554490T (da)
MA (1) MA49114A (da)
MX (1) MX2019007117A (da)
PH (1) PH12019501314A1 (da)
PL (1) PL3554490T3 (da)
PT (1) PT3554490T (da)
RS (1) RS62980B1 (da)
SA (1) SA519401971B1 (da)
SI (1) SI3554490T1 (da)
TW (1) TWI808952B (da)
UA (1) UA124977C2 (da)
WO (1) WO2018109152A1 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA47409A (fr) 2017-02-06 2019-12-11 Idorsia Pharmaceuticals Ltd Nouveau procédé de synthèse de 1-aryl-1-trifluorométhylcyclopropanes
KR102645911B1 (ko) 2017-07-05 2024-03-08 이도르시아 파마슈티컬스 리미티드 N-[1-(5-시아노-피리딘-2-일메틸)-1h-피라졸-3-일]-2-[4-(1-트리플루오로메틸-시클로프로필)-페닐]-아세타미드의 결정질 형태
US20220241258A1 (en) 2019-07-11 2022-08-04 Praxis Precision Medicines, Inc. Formulations of t-type calcium channel modulators and methods of use thereof
CA3161908A1 (en) * 2019-12-20 2021-06-24 Michael Ambuehl Pharmaceutical compositions comprising n-[1-(5-cyano-pyridin-2-ylmethyl)-1h-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide
CA3177277A1 (en) * 2020-04-29 2021-11-04 Kiran Reddy Methods of use of t-type calcium channel modulators
WO2023240205A1 (en) 2022-06-10 2023-12-14 Neurocrine Biosciences, Inc. Deuterated compounds

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3121076A (en) 1964-02-11 Benzodiazepinones and processes
US2948718A (en) 1960-08-09 New n-heterocyclic compounds
US2409754A (en) 1946-10-22 Method for obtaining hydantoins
US1025872A (en) 1911-09-06 1912-05-07 Farbenfab Vorm Bayer F & Co Phenylethylbarbituric acid.
US2554816A (en) 1950-04-04 1951-05-29 American Cyanamid Co Heterocyclic sulfonamides and methods of preparation thereof
US2884444A (en) 1956-01-13 1959-04-28 Carter Prod Inc 2-phenyl-1,3 propane diol dicarbamate
GB1039113A (en) 1964-08-06 1966-08-17 Ucb Sa New n-substituted lactams
US3984398A (en) 1966-12-14 1976-10-05 Roussel-Uclaf 1,5-Benzodiazepine-2,4-diones
CH500196A (de) 1969-03-10 1970-12-15 Ciba Geigy Ag Verfahren zur Herstellung von neuen Azepinderivaten
BE795893A (fr) 1972-02-28 1973-06-18 Unicler Derives de (methylene dioxy-3,4 phenyl)-1 dimethyl-4,4 pentene-1, leur preparation et leur application en therrapeutique
DE2460891C2 (de) 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
GB1597796A (en) 1978-05-15 1981-09-09 Ici Ltd Primidone preparation
ZA803250B (en) 1979-06-01 1982-01-27 Wellcome Found Substituded aromatic compounds
US4789680A (en) 1982-12-23 1988-12-06 Ciba-Geigy Corporation Aralkyltriazole compounds
GB8412357D0 (en) 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
CA2028782C (en) 1989-11-07 2003-10-14 Christian T. Goralski Process for the production of vinyl-gaba
DE4200259A1 (de) 1992-01-08 1993-07-15 Asta Medica Ag Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung
MX9700068A (es) 1994-06-24 1997-12-31 Euro Celtique Sa Compuestos y metodo para inhibir a la fosfodiesterasa iv.
IT1285801B1 (it) 1996-10-10 1998-06-24 Sigma Tau Ind Farmaceuti Procedimento migliorato per la preparazione dell'acido valproico
HUP0000735A3 (en) 1996-12-23 2002-03-28 Bristol Myers Squibb Pharma Co Nitrogen containing heteroaromatics as factor xa inhibitors
AU2001273040A1 (en) 2000-06-27 2002-01-08 Du Pont Pharmaceuticals Company Factor xa inhibitors
EP1353674A1 (en) 2000-12-29 2003-10-22 Alteon, Inc. Method for treating glaucoma ivb
EP1359911A2 (en) 2000-12-29 2003-11-12 Alteon, Inc. Method for treating fibrotic diseases or other indications ivc
CA2465207C (en) 2001-11-01 2011-01-04 Icagen, Inc. Pyrazole-amides and -sulfonamides
JP4286146B2 (ja) 2001-12-18 2009-06-24 メルク エンド カムパニー インコーポレーテッド メタボトロピックグルタミン酸受容体−５のヘテロアリール置換ピラゾール系調節剤
ATE374194T1 (de) 2001-12-18 2007-10-15 Merck & Co Inc Heteroarylsubstituierte triazolmodulatoren des metabotropen glutamatarezeptors 5
SE0201658D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab Immediate release pharmaceutical formulation
WO2004089303A2 (en) 2003-04-03 2004-10-21 Merck & Co., Inc. Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5
CN100537564C (zh) 2003-04-04 2009-09-09 麦克公司 代谢型谷氨酸受体-5的二芳基取代三唑调节剂
US20040220170A1 (en) 2003-05-01 2004-11-04 Atkinson Robert N. Pyrazole-amides and sulfonamides as sodium channel modulators
GB0328796D0 (en) 2003-12-12 2004-01-14 Biofocus Plc Compounds which interact with the G-protein coupled receptor family
WO2006018725A1 (en) 2004-08-18 2006-02-23 Pfizer Inc. Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same
AR052429A1 (es) 2004-12-23 2007-03-21 Glaxo Group Ltd Compuesto de arilpiridina, composicion farmaceutica que lo comprende, su uso para l a eleboracion de un medicamento y procedimiento para prepararlo
GB0508463D0 (en) 2005-04-26 2005-06-01 Glaxo Group Ltd Compounds
GB0508472D0 (en) 2005-04-26 2005-06-01 Glaxo Group Ltd Compounds
GB0515690D0 (en) 2005-07-29 2005-09-07 Portela & Ca Sa Asymmetric catalytic reduction
CA2634147A1 (en) 2005-12-22 2007-06-28 Icagen, Inc. Calcium channel antagonists
CN101466676B (zh) 2006-04-12 2012-07-18 默沙东公司 吡啶基酰胺类t-型钙通道拮抗剂
TW200812573A (en) * 2006-05-19 2008-03-16 Janssen Pharmaceutica Nv Co-therapy for the treatment of epilepsy and related disorders
MX2009000688A (es) 2006-07-24 2009-01-30 Hoffmann La Roche Pirazoles como activadores de glucocinasa.
US7902248B2 (en) 2006-12-14 2011-03-08 Hoffmann-La Roche Inc. Oxime glucokinase activators
WO2008085888A1 (en) 2007-01-05 2008-07-17 Arena Pharmaceuticals, Inc. G protein-coupled receptor and modulators thereof for the treatment of gaba-related neurological disorders including sleep-related disorders
AU2008266883B2 (en) 2007-06-20 2014-01-30 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
US20090030403A1 (en) 2007-07-27 2009-01-29 Leyde Kent W Methods and Systems for Attenuating the Tolerance Response to a Drug
BRPI0818501A2 (pt) 2007-10-08 2015-04-22 Advinus Therapeutics Private Ltd Derivados de acetamida como ativadores de glicoquinase, seu processo e aplicações medicinais
JP2011500807A (ja) 2007-10-24 2011-01-06 メルク・シャープ・エンド・ドーム・コーポレイション ピラジニルアミドｔ型カルシウムチャネルアンタゴニスト
WO2009054984A1 (en) 2007-10-24 2009-04-30 Merck & Co., Inc. Heterocycle phenyl amide t-type calcium channel antagonists
CA2702126A1 (en) 2007-10-24 2009-04-30 Merck Sharp & Dohme Corp. Heterocycle amide t-type calcium channel antagonists
WO2009118596A2 (en) 2008-03-26 2009-10-01 Glenmark Pharmaceuticals, S. A. Phthalimide derivatives as trpa1 modulators
EP2257340A2 (en) 2008-04-04 2010-12-08 BioMarin IGA Limited Compounds for treating muscular dystrophy
US7951814B2 (en) 2008-06-17 2011-05-31 Glenmark Pharmaceuticals, S.A. Quinazolinedione derivatives as TRPA1 modulators
WO2010073011A2 (en) 2008-12-23 2010-07-01 Betagenon Ab Compounds useful as medicaments
JP2012513409A (ja) 2008-12-23 2012-06-14 アボット・ラボラトリーズ 抗ウイルス化合物
AR076373A1 (es) 2009-04-24 2011-06-08 Glaxo Group Ltd N-pirazolil carboxamidas como inhibidores de canales de calcio
NZ596487A (en) 2009-06-04 2012-11-30 Novartis Ag 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES AND THE USE THEREOF AS PI3K INHIBITORS
WO2011022315A1 (en) 2009-08-19 2011-02-24 Merck Sharp & Dohme Corp. Pyrazinyl phenyl amide t-type calcium channel antagonists
WO2011053542A1 (en) 2009-10-30 2011-05-05 Merck Sharp & Dohme Corp. Heterocycle amide t-type calcium channel antagonists
WO2011084402A1 (en) 2009-12-21 2011-07-14 Merck Sharp & Dohme Corp. Tyrosine kinase inhibitors
WO2011093352A1 (ja) 2010-01-27 2011-08-04 武田薬品工業株式会社 チアゾール誘導体
EP2402327B1 (en) 2010-06-29 2018-03-07 Impetis Biosciences Ltd. Acetamide compounds as glucokinase activators, their process and medicinal applications
EP2609092B1 (en) 2010-08-26 2015-04-01 Boehringer Ingelheim International GmbH Oxadiazole inhibitors of leukotriene production
KR20120063283A (ko) 2010-12-07 2012-06-15 제일약품주식회사 신규한 피라졸로 피리딘 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 포함하는 약학적 조성물
SG191309A1 (en) 2011-01-18 2013-07-31 Glaxo Group Ltd Process for the preparation of retigabine
MX341977B (es) 2011-03-07 2016-09-07 Pfizer Derivados de fluoro-piridinona utiles como agentes antibacterianos.
US8759380B2 (en) 2011-04-22 2014-06-24 Cytokinetics, Inc. Certain heterocycles, compositions thereof, and methods for their use
UY34200A (es) 2011-07-21 2013-02-28 Bayer Ip Gmbh 3-(fluorovinil)pirazoles y su uso
EP2747770A1 (en) * 2011-08-26 2014-07-02 BIAL - Portela & Cª S.A. Treatments involving eslicarbazepine acetate or eslicarbazepine
US9006235B2 (en) 2012-03-06 2015-04-14 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
WO2014179564A1 (en) 2013-05-01 2014-11-06 Vitae Pharmaceuticals, Inc. Thiazalopyrrolidine inhibitors of ror-gamma
AR096393A1 (es) 2013-05-23 2015-12-30 Bayer Cropscience Ag Compuestos heterocíclicos pesticidas
CN103948553A (zh) * 2014-04-22 2014-07-30 青岛市中心医院 一种拉莫三嗪缓释片及其制备方法
KR101685993B1 (ko) 2014-05-15 2016-12-13 한국과학기술연구원 전압개폐 칼슘이온채널 억제 활성화능을 갖는 ｎ-(피라졸릴메틸)아릴설폰아마이드 화합물 및 이를 포함하는 약학적 조성물
AR100712A1 (es) * 2014-06-03 2016-10-26 Actelion Pharmaceuticals Ltd Compuestos de pirazol como bloqueadores de los canales de calcio tipo t
MX367519B (es) 2014-09-15 2019-08-26 Idorsia Pharmaceuticals Ltd Compuestos triazolicos como bloqueadores de canales de calcio tipo t.
BR112017016488A2 (pt) 2015-01-30 2018-04-10 Neurocrine Biosciences Inc triazóis substituídos e métodos relacionados aos mesmos
MA47409A (fr) 2017-02-06 2019-12-11 Idorsia Pharmaceuticals Ltd Nouveau procédé de synthèse de 1-aryl-1-trifluorométhylcyclopropanes
KR102645911B1 (ko) 2017-07-05 2024-03-08 이도르시아 파마슈티컬스 리미티드 N-[1-(5-시아노-피리딘-2-일메틸)-1h-피라졸-3-일]-2-[4-(1-트리플루오로메틸-시클로프로필)-페닐]-아세타미드의 결정질 형태

Also Published As

Publication number Publication date
HUE058360T2 (hu) 2022-07-28
IL267306B (en) 2022-07-01
PH12019501314A1 (en) 2020-03-02
MA49114A (fr) 2020-03-25
EP3554490B1 (en) 2022-02-16
CN110072521B (zh) 2022-11-29
PL3554490T3 (pl) 2022-05-30
SA519401971B1 (ar) 2022-12-27
KR102296653B1 (ko) 2021-09-01
TWI808952B (zh) 2023-07-21
MX2019007117A (es) 2019-09-16
AU2017378092A1 (en) 2019-07-25
TW201827048A (zh) 2018-08-01
ES2908641T3 (es) 2022-05-03
WO2018109152A1 (en) 2018-06-21
UA124977C2 (uk) 2021-12-22
JP7198792B2 (ja) 2023-01-04
JP6931701B2 (ja) 2021-09-08
RS62980B1 (sr) 2022-03-31
AU2023282336A1 (en) 2024-01-18
LT3554490T (lt) 2022-04-25
IL267306A (en) 2019-08-29
AU2017378092B2 (en) 2023-11-23
SI3554490T1 (sl) 2022-04-29
EA201991428A1 (ru) 2019-12-30
EP3554490A1 (en) 2019-10-23
JP2020180138A (ja) 2020-11-05
US20200016139A1 (en) 2020-01-16
HRP20220463T1 (hr) 2022-05-27
KR20190096381A (ko) 2019-08-19
PT3554490T (pt) 2022-03-17
CL2019001628A1 (es) 2019-11-15
CA3046846A1 (en) 2018-06-21
US11213517B2 (en) 2022-01-04
KR20210065206A (ko) 2021-06-03
JP2019536788A (ja) 2019-12-19
BR112019011208A2 (pt) 2019-10-15
CN110072521A (zh) 2019-07-30

Similar Documents

Publication Publication Date Title
DK3554490T3 (da) Farmaceutisk kombination omfattende en calciumkanalblokker type T
BR112017022691A2 (pt) inibidor de bromodomínio.
IT201600084952A1 (it) Coglifrutta.
ITUB20154007A1 (it) Dispositivo di tenuta per un gruppo cuscinetto-mozzo.
DK3347360T3 (da) Forbindelser, som er anvendelige til inhibering af ror-gamma-t
ES1150114Y (es) Abarcón.
ITUA20161830A1 (it) Sedia a rotelle.
CL2020001658S1 (es) Empaque.
DK3538234T3 (da) Forlystelse, især en rutsjebane
DK3728220T3 (da) Farmaceutiske forbindelser
DK3668806T3 (da) Signaleringsmekanisme.
CL2018000776A1 (es) Composicion agroquimica.
DK3295909T3 (da) Forbindingsmateriale til et punktur- eller infusionssted, særlig til hæmodialyse
FR3074817B1 (fr) Element modulaire de caniveau
ES1177734Y (es) Andamio de fachada.
FR3046350B1 (fr) Chariot- portoir pour un brancard.
ZA201904614B (en) Pharmaceutical combination comprising a t-type calcium channel blocker
CL2019001722S1 (es) Porción de dispensador.
CL2019001721S1 (es) Porción de dispensador.
CL2019001723S1 (es) Dispensador.
IT201700087916A1 (it) Dispositivo a scorrimento per costruzioni
ES1187460Y (es) Noray.
IT201700118826A1 (it) giandujamarcobava.it
IT201700027598A1 (it) Passerella frangiflutti.
IT201700047063U1 (it) Imballaggio perfezionato.